IDIrem Demiray

Irem Demiray

*This is an algorithmically generated author record based on publicly available information.

Irem Demiray has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A Decade of Durable Mechanical Circulatory Support with HeartMate 3 Across Age Groups in a Single-Center Experience

    by Sedat Karaca, Umit Kahraman, Aysen Yaprak Kapkin, Ahmet Daylan, Osman Nuri Tuncer, Irem Demiray, Cagatay Engin, Tahir Yagdi

    Background: Long-term real-world data after HeartMate 3 implantation remain limited, particularly regarding age-specific outcomes. We evaluated on-device survival and major adverse events across nearly a decade of experience. Methods: This retrospective single-center study included 215 patients undergoing primary HeartMate 3 implantation between January 2016 and October 2025. On-device mortality was analyzed using Aalen–Johansen cumulative incidence estimates with heart transplantation as a competing event; age-group differences were assessed using Fine–Gray regression. Transplant-censored Kaplan–Meier survival was examined secondarily, and mortality predictors were evaluated using multivariable Cox regression. Results: Median age was 53 years and median support was 603 days. At data cutoff, 149 patients remained alive on support, eight underwent transplantation, and 58 died on support. At 5 years, the cumulative incidences of on-device death and heart transplantation were 35.3% and 4.1%, respectively, with no significant age-group difference (Fine–Gray global p = 0.088). In the secondary transplant-censored Kaplan–Meier analysis, estimated survival was 87.4% at 30 days, 81.1% at 1 year, and 63.8% at 5 years. Higher preoperative creatinine was associated with mortality (HR, 1.93 per 1-mg/dL increase; 95% CI, 1.07–3.50; p = 0.029). No intrinsic pump thrombosis occurred. Conclusions: HeartMate 3 provided durable support with favorable long-term survival, although non-pump adverse events remained clinically relevant.

  • Open Access

    Sutureless Aortic Valve Replacement with the Perceval Plus® Versus TAVI: A Propensity-Matched Analysis of Postoperative Outcomes, Hematological Dynamics, and Inflammatory Response

    by Umit Kahraman, Irem Demiray, Serkan Ertugay, Emrah Oguz, Oguz Yavuzgil, Hakan Posacioglu, Anıl Ziya Apaydin, Ismet Tanzer Calkavur, Mustafa Ozbaran, Tahir Yagdi

    Perceval Plus and TAVI are increasingly used for severe aortic stenosis, both relying on a self-expanding nitinol stent design, yet evidence specific to Perceval Plus remains limited regarding postoperative clinical outcomes and hematological and inflammatory dynamics. We compared postoperative clinical outcomes and longitudinal platelet/CRP dynamics between Perceval Plus and TAVI in a retrospective single-center cohort, in which 26 propensity score-matched pairs were obtained (1:1 matching) from patients undergoing Su-AVR (Perceval Plus, n = 53) or TAVI (self-expanding Medtronic devices, n = 101). Mortality, echocardiographic outcomes, and rates of postoperative atrial fibrillation and conduction disturbances showed no statistically significant differences between groups, while TAVI was associated with shorter ICU and hospital stay and Su-AVR required higher FFP transfusion (p = 0.016). Platelet count declined in both groups, with a deeper nadir in Su-AVR (postoperative day 3: 66% decline) versus TAVI (day 4: 27% decline), with a significant group × time interaction (p = 0.013); CRP rose in both groups but more rapidly and to a greater magnitude in Su-AVR (time and group × time interaction, both p < 0.001). Su-AVR and TAVI showed no statistically significant differences in the clinical safety outcomes assessed but differed in postoperative hematological and inflammatory magnitude, likely reflecting multifactorial procedure- and device-related mechanisms, warranting confirmation in larger, prospective, multicenter studies.